XT
ARTV

XTX Topco’s Artiva Biotherapeutics ARTV Stock Holding History

XTX Topco’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131K Buy
+20,270
New +$100K ﹤0.01% 3013
2025
Q4 		– Sell
-47,973
Closed -$138K – 3915
2025
Q3 		$138K Buy
+47,973
New +$128K 0.01% 1952

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

XTX Topco's ARTV Position: Q1 2026 in Review

XTX Topco opened a new position in Artiva Biotherapeutics (ARTV) in Q1 2026: 20,270 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #3013 among its holdings. This is a return to the name: XTX Topco previously reported a position in ARTV as recently as Q3 2025.

XTX Topco first reported a position in ARTV in Q3 2025 and has held it in 2 quarters since. The position peaked at $138K in Q3 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • XTX Topco held 20,270 shares of Artiva Biotherapeutics worth $131K as of Q1 2026.
  • Artiva Biotherapeutics was a new XTX Topco position in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3013 holding.
  • XTX Topco first reported a position in Artiva Biotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • XTX Topco's Artiva Biotherapeutics position peaked at $138K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.